Clinical Outcomes Associated with Polymyxin B Dose in Patients with Bloodstream Infections Due to Carbapenem-Resistant Gram-Negative Rods

There is significant variation in the use of polymyxin B (PMB), and optimal dosing has not been defined. The purpose of this retrospective study was to evaluate the relationship between PMB dose and clinical outcomes. We included patients with bloodstream infections (BSIs) due to carbapenem-resistan...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Antimicrob Agents Chemother
Asıl Yazarlar: Nelson, Brian C., Eiras, Daniel P., Gomez-Simmonds, Angela, Loo, Angela S., Satlin, Michael J., Jenkins, Stephen G., Whittier, Susan, Calfee, David P., Furuya, E. Yoko, Kubin, Christine J.
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: American Society for Microbiology 2015
Konular:
Clinical Therapeutics
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC4604419/
https://ncbi.nlm.nih.gov/pubmed/26324272
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1128/AAC.00844-15
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller